Dei BioPharma receives second US FDA approval for key diabetes drug
Dei BioPharma projects $15B in annual revenue after its development plan for two novel GLP-1 drugs, liraglutide and semaglutide, is ...
Dei BioPharma projects $15B in annual revenue after its development plan for two novel GLP-1 drugs, liraglutide and semaglutide, is ...
© 2024 Ugstandard - Latest News by Digital/New Media company.